SignalDailyGlobal signals. Global context.

Market Incident

Public · Developing

AI compiled from Infoway · 4 analyzed stories

Precision BioSciences (DTIL) Reports $108.0M Cash and Runway Through 2028

Precision BioSciences reported about $108.0M in cash, cash equivalents and restricted cash as of September 30, 2026, and expects its cash to last through 2028. Its third-quarter net loss was $7.6M, or $0.28 per share, compared with $21.8M, or $1.84 per share, a year earlier.

Published:

Updated:

What happened

Precision BioSciences reported about $108 million in cash, cash equivalents, and restricted cash as of September 30, 2026. It expects that cash to fund operations through 2028. The company also reported a third-quarter net loss of $7.6 million, compared with $21.8 million a year earlier.

Global impact / market context

The stated cash runway may reduce near-term concerns about how the company will pay for its work. But the estimate depends on execution and financing assumptions, and the company reported a loss. The supplied information does not show how investors reacted.

What to watch

  1. Check whether the company continues to report enough cash to support its operations through 2028; this shows whether the stated runway still holds.
  2. Check whether the lead hepatitis B and Duchenne muscular dystrophy trials continue to advance; progress is part of the company's reported outlook.
  3. Check future losses and revenue, including whether revenue continues to rely on milestone payments; these figures help show how the company's finances are changing.

Affected assets

  • Precision BioSciences, Inc.

Evidence